New rules bring stem cell, gene therapies under Central licensing net

📌 Summary:

• The Union Health Ministry amended the Drugs Rules, 1945 to bring cell and stem cell products, gene therapies, and xenografts under the Central Licence Approving Authority (CLAA) framework
• The change closes a long-standing regulatory gap in India’s oversight of advanced (cell and gene) therapies
• Officials clarified (July 4, 2026) that the amendment does NOT amount to automatic approval, nor will it immediately make therapies cheaper or more accessible
• Manufacturers must still prove safety, quality and efficacy, secure clinical-trial and marketing approvals, and comply with the Drugs and Cosmetics Act
• Both Central and State licensing authorities will now jointly oversee these products, laying the groundwork for safer, more reliable access over time

🎯 UPSC Relevance: GS3 Science & Technology — regulation of advanced biotechnology therapies; balancing innovation and patient safety; role of CDSCO/CLAA in drug regulation.

📝 Prelims Facts:

• The amendment is to the Drugs Rules, 1945 (under the Drugs and Cosmetics Act)
• CLAA = Central Licence Approving Authority
• Products covered: cell & stem cell products, gene therapies, and xenografts

🔑 Key Term: Xenograft — tissue or an organ transplanted from one species to another (e.g., animal to human), now brought under Central licensing oversight in India.